Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BioVaxys Acquires Critical Lipid Supply for DPX Platform | Contract Pharma

What are you searching for?

Sign in
Breaking News

BioVaxys Acquires Critical Lipid Supply for DPX Platform

Prepares for preclinical and clinical program ramp-up.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

In anticipation of restarting clinical studies of various DPX formulations and initiating new preclinical studies, BioVaxys Technology Corp. has acquired a 48-kilogram supply of GMP-grade lipid to enable production of the Company’s DPX antigen packaging delivery platform.
 
These unused lipids from the former IMV Inc., had been previously produced in advance of anticipated IMV clinical studies and commercial ramp-up. In February 2024, BioVaxys acquired 100% of the intellectual property and programs formerly owned by IMV.
 
BioVaxys’ DPX technology, is a patented delivery platform that can package/deliver a range of bioactive molecules, such as mRNA/polynucleotides, peptides/proteins, virus-like particles, and small molecules, to produce targeted, long-lasting immune responses enabled by various formulated components. The DPX platform, which is non-aqueous and non-systemic, facilitates immune cell recruitment and antigen uptake at the injection site for delivery to regional lymph nodes via Antigen Presenting Cells, stimulating a robust and durable antigen-specific immune response.
 
Kenneth Kovan, President & Chief Operating Officer of BioVaxys stated, “We were able to acquire the lipids on commercially attractive terms, with 48 kg of lipid anticipated to cover production for any conceivable preclinical or clinical trials over the next several years and save the Company over one year in manufacturing lead time for this drug substance.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics